25.09.2013Paul Scherrer Lunch Symposium, 12:00-13:30 BioValley Life Science WeekYou are hereEventsLife science events Paul Scherrer Lunch Symposium, 12:00-13:30 BioValley Life Science Week
The expertise and infrastructure of the Paul Scherrer Institute (PSI) are open to companies. With this event we would like to encourage greater use of our facilities by industrial researchers and present the benefits of the various methods available at the Swiss Light Source.
LS2 Annual Meeting 201812.02.2018The biggest Life Sciences conference in Switzerland takes place at the University of Lausanne February 12-13, 2018
Bilan - Les Métiers de DemainLe magazine référence nous informe des nouvelles formations et de leur impact sur l'avenir des métiers de la santé...
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.